Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Celularity Partnership with Vesalius Longevity Labs Inc.
Celularity entered into an exclusive manufacturing and commercial collaboration with Vesalius Longevity Labs to establish a U.S.-based manufacturing and supply platform for Peptual-branded peptide active pharmaceutical ingredients (APIs). Celularity will utilize its Florham Park, New Jersey facility to perform downstream purification, processing, and analytical testing of bulk peptide material under cGMP standards.
ADT Inc. has entered into a definitive agreement to be acquired by Thrive Holdings in an all-cash transaction valued at approximately $15.3 billion in enterprise value. ADT stockholders will receive $10.00 per share, representing a 45.6% premium to the unaffected closing price, and the company will become privately held upon completion.
Value
$15.3B
Counterparty
Thrive Holdings
“ADT is pleased to enter into this transaction, which recognizes the value built by our more than 12,000 employees and delivers an attractive cash premium to our stockholders. Our leadership in security is based on a legacy of trust, longstanding customer relationships and the dedication of our employees. With Thrive Holdings’ long-term capital and technology expertise, ADT will gain new opportunities to accelerate innovation, enhance the customer experience and bring greater peace of mind to even more homes and businesses.”
Jim DeVries, Chairman, President and Chief Executive Officer of ADT
Inflection Point Acquisition Corp. VI Signs $300M M&A Deal with Quantum Space, LLC
Inflection Point Acquisition Corp. VI announced that the SEC has declared effective its Registration Statement on Form S-4 for its previously announced business combination with Quantum Space, LLC. The deal includes approximately $300 million in committed PIPE financing and a shareholder vote is scheduled for November 20, 2026. Upon closing, the combined company will be renamed Quantum Space, Inc. and is expected to trade on the NYSE under the ticker QSPC.
Varex Imaging M&A Deal with Teledyne Technologies Incorporated
Varex Imaging Corporation stockholders approved the company's acquisition by Teledyne Technologies Incorporated at a special meeting held on October 28, 2026. Approximately 77% of outstanding shares were represented, with the merger agreement adoption receiving overwhelming support. The transaction remains subject to regulatory approvals, including Hart-Scott-Rodino clearance and foreign investment laws.
Perrigo Company plc has entered into a definitive agreement to divest its Infant Formula business to MeridianMade for up to $175 million, consisting of $40 million in cash and $135 million in performance-based milestones. The deal advances Perrigo's 'Three-S' plan to streamline its portfolio and focus on core consumer self-care products. The transaction is expected to close in the first half of 2027, subject to regulatory approvals.
Canton Strategic Holdings announced an agreement with TSV LLC to make its common stock available as the first tokenized U.S. equity for 24/7 trading on the Canton Network. The company has engaged Fairmint, an SEC-registered onchain transfer agent, to issue the tokenized shares, which are expected to begin trading as early as November 2, 2026.
Processa Pharmaceuticals announced that the FDA has cleared its Investigational New Drug (IND) application for VT-7208, allowing the company to initiate a Phase 2 study in patients with chronic spontaneous urticaria. The company also appointed Dr. Sheila Gujrathi as Executive Chair and entered into a research collaboration with Generian Pharmaceuticals to expand its pipeline.
Eightco Holdings' subsidiary, AI Innovation Capital LLC, completed the sale of a portion of its indirect interest in OpenAI Group, PBC for $20 million in cash. The monetization was executed at a price approximately 40% above the initial purchase price, and the company intends to use the proceeds to accelerate its existing $125 million share repurchase program.
Maplebear Inc. (Instacart) has entered into a definitive agreement to be acquired by DoorDash, Inc. for $65.00 per share, representing an equity value of approximately $17 billion. The transaction consideration will be at least 75% cash, with Instacart stockholders able to elect cash, DoorDash stock, or a combination of both, subject to proration.
Centrus Energy has completed and shipped the first new centrifuge from its Oak Ridge, Tennessee, manufacturing plant to support a multi-billion-dollar expansion of its uranium enrichment capacity in Ohio. This milestone marks the transition to high-rate manufacturing and the establishment of a complete, unobligated domestic supply chain for both commercial and national security markets.
DoorDash has entered into a definitive agreement to acquire Instacart for $65.00 per share, representing an equity value of approximately $17 billion. The consideration will be at least 75% cash, with Instacart stockholders able to elect cash, DoorDash stock, or a combination of both, subject to a 25% cap on the total stock component.
Value
$17B
Counterparty
Maplebear Inc. (d.b.a. Instacart)
“Grocery is one of the hardest things to get right online. Someone has to pick a ripe avocado, find a substitute you’d choose yourself, and get the ice cream to you before it melts. Instacart has spent years learning to do that well for grocers, while DoorDash has built a delivery network and technology that local stores rely on every day. Together, we could give stores of every size more of those tools and unlock the potential of grocery delivery. It’s still early innings, but we know that when more people shop local, more dollars stay local.”
Coherus Oncology announced interim clinical data from its TREGCHECK program evaluating tagmokitug, a cytolytic CCR8 antibody, in combination with toripalimab for esophageal squamous cell carcinoma (ESCC). The study reported a 75% confirmed overall response rate (cORR) in first-line ESCC patients irrespective of PD-L1 status, which increased to 89% following the data cutoff. The results provide clinical proof-of-concept for tagmokitug and support the expansion of enrollment in both first-line and second-line ESCC cohorts.
Foster L B Signs $52.2M M&A Deal with Dulworth Enterprises, Inc.
L.B. Foster Company, through its subsidiary CXT Incorporated, acquired the operating assets of Texas-based Dulworth Enterprises, Inc. for $52.18 million in cash. The acquisition expands L.B. Foster's precast concrete business into residential wastewater and aerobic treatment systems, adding approximately $18 million in annual revenue.
Arxis Signs $770M M&A Deal with Omnetics Connector Corporation
Arxis, Inc. filed an amendment to its previous 8-K to provide required financial statements and pro forma information following its $770 million acquisition of Omnetics Connector Corporation. The deal, which closed on August 17, 2026, involved the issuance of 13,351,964 shares of Class A common stock and the funding of $8 million in cash escrow accounts.
Valion Bio announced positive final safety data from a NIAID-funded study of its lead biologic candidate, Entolimod, conducted by the Armed Forces Radiobiology Research Institute (AFRRI). The study found no evidence of treatment-related toxicity or hematologic disruption in mice, supporting the advancement to a fully funded therapeutic study evaluating survival and gastrointestinal recovery following radiation exposure.
INmune Bio Inc. entered into a securities purchase agreement with a single institutional investor for a $4.5 million registered direct offering and concurrent private placement. The company is issuing 3,000,000 shares of common stock at $1.50 per share along with warrants to purchase an additional 3,000,000 shares at an exercise price of $1.65. Proceeds are intended for working capital and general corporate purposes.
Maplebear Inc. (Instacart) has entered into a definitive agreement to be acquired by DoorDash in a cash-and-stock transaction valued at approximately $17 billion. The announcement was made alongside the company's Q3 2026 financial results, which showed 17% revenue growth and $147 million in GAAP net income. Due to the pending acquisition, Instacart has cancelled its earnings conference call and suspended its forward-looking guidance.
Value
$17B
Counterparty
DoorDash, Inc.
“Q3 was our best quarter as a public company, with GTV up 15% year-over-year and advertising and other revenue up 23% year-over-year. Our fundamentals keep getting stronger, with solid consumer demand, deepening customer engagement, and expanding profitability.”
Chris Rogers, CEO
“Online grocery is still an underpenetrated category, and we’re in the early stages of realizing what our purpose-built grocery technology can do to transform it. That’s why we’re building the operating system for grocery: one integrated platform that powers ecommerce, fulfillment, in-store, retail media, and AI Solutions.”
New Era Energy & Digital entered into securities purchase agreements for a $64 million private placement (PIPE) of 23,272,727 shares of common stock at $2.75 per share. The company intends to use the proceeds to repay $36 million in debt under its Macquarie facility and to fund working capital for its Texas Critical Data Centers project.
DoorDash announced a definitive agreement to acquire Instacart for $65.00 per share, payable in at least 75% cash and up to 25% DoorDash common stock. The deal was announced alongside record Q3 2026 financial results, including $4.6 billion in revenue and $466 million in net income.
Counterparty
Maplebear Inc. ("Instacart")
“In Q3 2026, we generated new quarterly records across Marketplace GOV, revenue, and net income. In the quarter, we drove continued growth in our membership programs, launched new products, added more selection, advanced our global technology platform, and continued to innovate in key new areas of our business, including merchant services, AI, and autonomy.”
Tony Xu, Chief Executive Officer
“We believe that, together with Instacart, our combined scale and complementary technologies will enable us to build the next generation of tools and services that will empower local merchants to thrive, provide more choice for consumers, and generate more opportunity for Dashers and shoppers using Instacart's platform ("Shoppers").”
Kiora Pharmaceuticals entered into an exclusive license agreement with Senju Pharmaceutical to develop and commercialize KIO-401, a late-stage oral small-molecule calpain inhibitor for ophthalmic diseases, in all territories outside of Asia. Kiora will pay an upfront fee of $3.5 million, low teen millions upon technology transfer, and up to $168.5 million in potential regulatory and commercial milestones, plus single-digit royalties.
First Mid Bancshares Signs $70.7M M&A Deal with Evergreen Bancshares, Inc.
First Mid Bancshares, Inc. has entered into a definitive agreement to acquire Evergreen Bancshares, Inc., the parent company of American Bank of Freedom, in a stock and cash transaction valued at approximately $70.7 million. The deal expands First Mid's presence in St. Louis, Central Illinois, and Indianapolis, and is a strategic step to scale the organization above $10 billion in assets. Evergreen shareholders will receive 0.4081 shares of First Mid common stock and $5.20 in cash for each share held, with the transaction expected to close in the first quarter of 2027.
Value
$70.7M
Counterparty
Evergreen Bancshares, Inc.
“We have known the organization and its leadership for many years, and we are honored to have been selected as their strategic partner. This transaction strengthens our presence in St. Louis and along the I-70 corridor, expands our Illinois franchise through Rochester, and establishes a full-service banking presence in the greater Indianapolis market.”
Matthew Smith, President and Chief Executive Officer
“This is also an important step for First Mid as we continue to build scale and prepare our organization for growth above $10 billion in assets. We have made significant investments in our people, technology, risk management and operating infrastructure, and we believe the additional earnings and synergies from this transaction more than offset the incremental financial impact of operating above the $10 billion threshold while positively positioning First Mid for future opportunities.”
Matthew Smith, President and Chief Executive Officer
Indivior Pharmaceuticals M&A Deal with Supernus Pharmaceuticals, Inc.
Indivior reported record Q3 2026 financial results while providing a status update on its pending all-stock merger of equals with Supernus Pharmaceuticals. The merger, which has received shareholder approval, is expected to close on November 2, 2026, with the combined company operating as Supernus, Inc. (ticker: SUPN).
Counterparty
Supernus Pharmaceuticals, Inc.
“In the third quarter, we delivered record SUBLOCADE net revenue and record adjusted EBITDA, reflecting the strength of our business and the disciplined execution of the Indivior Action Agenda. Upon the imminent closing of our merger with Supernus, we will have successfully completed all three phases of the Indivior Action Agenda.”
Joe Ciaffoni, Chief Executive Officer
“We achieved record financial performance in the third quarter, including SUBLOCADE net revenue growth of 22% year-over-year and adjusted EBITDA margin of 59%, up 2100 basis points year-over-year.”
Star Equity Holdings Signs $500K M&A Deal with PD Machine, LLC
Star Equity Holdings acquired PD Machine, LLC, a Vernal, Utah-based machine shop, for $350,000 in cash and 75,000 shares of Series A Preferred Stock. The acquisition expands the company's Energy Services division by adding in-house machining, repair, and rebuild capabilities for drilling equipment. The deal also includes an option to acquire the related real estate for an additional $150,000 in cash and 35,000 preferred shares by February 2027.
Bunker Hill Mining Signs $20M M&A Deal with Silver47 Exploration Corp.
Bunker Hill Mining Corp. stockholders approved a strategic business combination with Silver47 Exploration Corp. at a special meeting held on October 28, 2026. The company also completed $20 million in drawdowns from its Teck and Ocean Partners facilities to support the ramp-up to commercial production, which is expected by the end of Q4 2026.
Value
$20M
Counterparty
Silver47 Exploration Corp.
“I wish to thank the combined Bunker Hill and Silver 47 shareholders for supporting this exciting transaction that will materially improve their exposure to US-based Silver and Critical Metals. This is a source of remarkable US-based investment value to be unlocked by the re-investment of cash flow generated by the Bunker Hill Mine, which remains on track to achieve commercial production by the end of 2026, supported by the drawdowns from the existing Teck and Ocean Partners facilities.”
Actuate Therapeutics closed an underwritten public offering of 30,985,900 shares of common stock and warrants to purchase 15,492,950 shares, raising gross proceeds of approximately $11.0 million. The offering was priced at $0.71 per set of two shares and one warrant, implying a per-share price of $0.355. The company intends to use the net proceeds for working capital and general corporate purposes.
The Bank of New York Mellon Corporation entered into an underwriting agreement for the public offering of 1,250,000 depositary shares, each representing a 1/100th interest in a share of Series O Noncumulative Perpetual Preferred Stock. The company filed a Certificate of Designations to establish the rights of the new Series O Preferred Stock, which includes certain restrictions on common stock dividends if preferred dividends are not paid.
Milestone Pharmaceuticals received a deficiency notice from Nasdaq on October 23, 2026, because its common shares failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has until April 21, 2027, to regain compliance by having its shares close at $1.00 or higher for at least 10 consecutive business days.
BRC Group Holdings M&A Deal with B. Riley Securities Holdings, Inc.
BRC Group Holdings completed a short-form merger of its indirect subsidiary, B. Riley Securities Holdings, Inc. (BRSH), after acquiring over 90% of BRSH's outstanding common stock. Remaining BRSH shareholders will receive $8.88 per share in cash, and outstanding restricted stock awards were converted into BRC common stock awards.
Santander Holdings USA M&A Deal with Webster Financial Corporation
Santander Holdings USA, Inc. (SHUSA) filed an amendment to include financial statements and pro forma information following Banco Santander's completed acquisition of Webster Financial Corporation on August 20, 2026. Immediately following the merger, Banco Santander contributed the assets and liabilities of Webster to its SHUSA subsidiary.
Geron Corporation is discontinuing its Phase 3 IMpactMF clinical trial of imetelstat in relapsed/refractory myelofibrosis based on a recommendation from an independent Data Monitoring Committee. The committee advised that the trial was unlikely to meet its primary endpoint of overall survival, although no new safety signals were observed.